Physician profile
Ashlee Fleming
NPI 1750857439
$6,377.74
in general payments reported to CMS, 2019-2025
31 companies · $1,845 in 2025
The $1,845 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,625 · 2022: $937 · 2023: $909 · 2024: $1,061 · 2025: $1,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,815.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,716.00 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,181.29 | 2021-2025 | |
| Janssen Biotech, INC. | $592.12 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $530.44 | 2021-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $347.70 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $259.12 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $173.80 | 2021-2023 | |
| Celltrion USA INC. | $172.81 | 2024-2025 | Vegzelma |
| Pfizer INC. | $155.99 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $147.68 | 2021-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $133.49 | 2025 | Voquezna |
| Gilead Sciences, INC. | $130.70 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $94.41 | 2021-2024 | Ocaliva |
| Celgene Corporation | $93.23 | 2021-2022 | |
| Daiichi Sankyo INC. | $91.01 | 2021-2025 | Injectafer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $84.24 | 2021-2025 | Rebyota |
| Genzyme Corporation | $61.51 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $53.76 | 2025 | Iqirvo |
| Novo Nordisk INC | $53.05 | 2024-2025 | Wegovy |
| Janssen Scientific Affairs, LLC | $51.65 | 2022 | |
| Lilly USA, LLC | $38.27 | 2024-2025 | Omvoh |
| Redhill Biopharma INC. | $36.04 | 2021 | |
| Madrigal Pharmaceuticals | $32.01 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $27.39 | 2024 | |
| Axsome Therapeutics, INC. | $23.40 | 2023 | Auvelity |
| Braintree Laboratories, INC. | $20.39 | 2024 | Suflave |
| Regeneron Healthcare Solutions, INC. | $18.65 | 2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.11 | 2023 | Cyltezo |
| Fresenius Kabi USA, LLC | $16.40 | 2023 | Idacio |
| Axonics, INC. | $14.46 | 2022 | |
| Organon LLC | $8.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlee Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.